HNGR Hanger Inc

Supplemental Disclosures to the Proxy Statement

The disclosure on pages 32 – 40 of the Proxy Statement under the heading “The Merger - Background of the Merger” is hereby supplemented by adding the underlined disclosure to the second full paragraph on page 33 of the Proxy Statement:

Beginning on March 31, 2022, BofA Securities initiated discussions with 14 potentially interested parties, all of which were financial sponsors, regarding whether such parties would have an interest in exploring a transaction with Hanger. Patient Square and Bidders A through I (as defined below) were included in such outreach. These discussions were conducted only based upon publicly available information given the parties had not yet entered into confidentiality agreements. Following this initial outreach, Hanger entered into confidentiality agreements with 12 potentially interested parties. Patient Square entered into a confidentiality agreement with Hanger on April 11, 2022. All of the confidentiality agreements, including the confidentiality agreement with Patient Square, included substantially similar “standstill” provisions with “don’t-ask-don’t-waive” language intended to cause interested parties to submit their highest and best proposals in a competitive auction environment pursuant to the Sale Transaction Process. Each party that entered into a confidentiality agreement received certain process materials from BofA Securities, including the Hanger presentation. The remaining two parties that did not enter into confidentiality agreements indicated they were not interested in pursuing a transaction with Hanger for a variety of reasons.

The disclosure on pages 41 – 45 of the Proxy Statement under the heading “The Merger - Recommendation of Our Board of Directors and Reasons for the Merger - Reasons for the Merger” is hereby supplemented by adding the underlined disclosure to the fifth full bullet paragraph on page 42 of the Proxy Statement:

The disclosure on pages 47 – 48 of the Proxy Statement under the heading “The Merger - Fairness Opinion of BofA Securities, Inc. - Hanger Financial Analyses - Selected Publicly Traded Companies Analysis” is hereby supplemented by adding the underlined disclosure to the third full paragraph on page 47 of the Proxy Statement:

BofA Securities reviewed publicly available financial and stock market information for Hanger and the following 10 publicly traded companies in the outsourced physician services and post-acute care and rehabilitation businesses, which companies were selected based upon BofA Securities’ professional judgment and experience:

The disclosure on pages 48 – 50 of the Proxy Statement under the heading “The Merger - Fairness Opinion of BofA Securities, Inc. - Hanger Financial Analyses - Selected Precedent Transactions Analysis” is hereby supplemented by adding the underlined disclosure to the last paragraph on page 48 of the Proxy Statement:

BofA Securities reviewed, to the extent publicly available, financial information relating to the following 15 selected transactions involving companies in the rehabilitation, outsourced physician services, post-acute care and specialty patient care businesses, which transactions were selected based upon BofA Securities’ professional judgment and experience:

The disclosure on pages 48 – 50 of the Proxy Statement under the heading “The Merger - Fairness Opinion of BofA Securities, Inc. - Hanger Financial Analyses - Selected Precedent Transactions Analysis” is hereby supplemented by adding the column “Closing Date” and the related underlined disclosure to the table on page 49 of the Proxy Statement:

The disclosure on pages 48 – 50 of the Proxy Statement under the heading “The Merger - Fairness Opinion of BofA Securities, Inc. - Hanger Financial Analyses - Selected Precedent Transactions Analysis” is hereby supplemented by adding the underlined disclosure and deleting the text that is struck through in the last paragraph on page 49 of the Proxy Statement:

BofA Securities reviewed transaction values, calculated as the enterprise value implied for the target company based on the consideration payable in the selected transaction, as a multiple of the target company’s latest 12 months (“LTM”) Adjusted EBITDA. The overall low to high transaction value / LTM Adjusted EBITDA multiples observed for the selected transactions were 8.9x to 18.2x (with a mean of 11.4x and a median of 11.0x). Based on its professional judgment and experience and after taking into consideration, among other things, the observed data for the selected precedent transactions, BofA Securities then applied a selected range of transaction value / LTM Adjusted EBITDA multiples of 9.5x to 11.5x to Hanger’s LTM EBITDA as of the end of the first quarter of 2022. Estimated financial data of the selected transactions were based on publicly available information at the time of announcement of the relevant transaction, and estimated financial data of Hanger were based on the Management Forecasts. This analysis indicated the following approximate implied per share value reference ranges for Hanger, rounded to the nearest $0.25, as compared to the Merger Consideration:

The disclosure on page 50 of the Proxy Statement under the heading “The Merger - Fairness Opinion of BofA Securities, Inc. - Hanger Financial Analyses – Discounted Cash Flow Analysis” is hereby supplemented by adding the underlined disclosure to the second paragraph on page 50 of the Proxy Statement:

BofA Securities performed a discounted cash flow analysis of Hanger to calculate the estimated present value of the standalone unlevered, after-tax free cash flows that Hanger was forecasted to generate during Hanger’s fiscal year 2022 (second through fourth quarters) through fiscal year 2026 based on the Management Forecasts. BofA Securities calculated terminal values for Hanger by applying terminal forward multiples of 8.5x to 10.5x, based on the historical trading range for the Hanger stock as a multiple of Adjusted EBITDA burdened by stock based compensation (fiscal year 2026), as set forth in “— Certain Financial Projections”, to the terminal year Adjusted EBITDA. BofA Securities subtracted from the range of terminal enterprise values it derived for Hanger, net debt of $482 million (“net debt”) as of March 31, 2022, which amount includes $520 million of debt and $37 million of cash as of March 31, 2022, per the latest available public filings. The cash flows and terminal values were then discounted to present value as of March 31, 2022 using discount rates ranging from 7.75% to 9.25%, which were based on an estimate of Hanger’s weighted average cost of capital. This analysis indicated the following approximate implied per share value reference ranges for Hanger, rounded to the nearest $0.25, as compared to the Merger Consideration:

The disclosure on pages 52 – 54 of the Proxy Statement under the heading “The Merger - Certain Financial Projections” is hereby supplemented by adding the row “Adjusted EBITDA burdened by stock based compensation” and the related underlined disclosure and deleting the text that is struck through in the table and related footnotes on page 52 of the Proxy Statement:

The disclosure on pages 52 – 54 of the Proxy Statement under the heading “The Merger - Certain Financial Projections – Important Information Regarding the Management Forecasts” is hereby supplemented by adding the underlined disclosure and deleting the text that is struck through in the second full paragraph on page 53 of the Proxy Statement:

Adjusted EBITDA contained in the Management Forecasts and Adjusted EBITDA burdened by stock based compensation and Unlevered Free Cash Flow derived from the Management Forecasts, both each as summarized above, are each a “non-GAAP financial measure,” which is a financial performance measure that is not calculated in accordance with GAAP. The non-GAAP financial measures used in the Management Forecasts were relied upon by BofA Securities for purposes of its opinion and by the Board in connection with its evaluation of the Merger. The SEC rules which would otherwise require a reconciliation of a non-GAAP financial measure to a GAAP financial measure do not apply to non-GAAP financial measures included in disclosures relating to a proposed business combination such as the Merger if the disclosure is included in a document such as this proxy statement. In addition, reconciliations of non-GAAP financial measures were not relied upon by BofA Securities for purposes of its opinion or by the Board in connection with its evaluation of the Merger. Accordingly, Hanger has not provided a reconciliation of the financial measures included in the Management Forecasts to the relevant GAAP financial measures. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures as used by Hanger may not be comparable to similarly titled amounts used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly, this non-GAAP financial measure should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP.

The disclosure on page 54 of the Proxy Statement under the heading “The Merger - Interests of Directors and Executive Officers of Hanger in the Merger” is hereby supplemented by adding the underlined disclosure in a new paragraph which follows the second full paragraph on page 54 of the Proxy Statement:

In addition to interests in the Merger that may be different from, or in addition to, your interests as a stockholder generally, our directors and executive officers also own shares of Hanger common stock for which they are entitled to receive the Merger Consideration of $18.75 per share, like all our stockholders. See “Security Ownership of Certain Beneficial Owners and Management” for more information about the Hanger common stock they own. 

Antitrust Update

Effective as of 11:59 p.m. Eastern Time on September 1, 2022, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Merger. That same day, the period during which the Washington Attorney General may have requested more information about the Merger pursuant to the requirements of Washington Revised Code 19.390.010, et. seq., a statute pertaining to certain health care transactions in the State of Washington, also expired. Under the Washington Revised Code, the waiting period for completion of the Merger will expire on October 1, 2022.

Forward-Looking Statements

This report contains statements that are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include information concerning the proposed Merger and the ability to consummate the proposed Merger, our liquidity and our possible or assumed future results of operations, including descriptions of our business strategies. These statements often include words such as “believe,” “expect,” “project,” “potential,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “would,” “should,” “could,” “forecasts” or similar words. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. We believe these assumptions are reasonable, but you should understand that these statements are not guarantees of performance or results, and our actual results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent releases or reports. These statements involve risks, estimates, assumptions, and uncertainties that could cause actual results to differ materially from those expressed in these statements and elsewhere in this report. These uncertainties include, but are not limited to, the inability to consummate the Merger within the anticipated time period, or at all, due to any reason, including the failure to obtain required regulatory approvals, satisfy the other conditions to the consummation of the Merger or complete necessary financing arrangements; the risk that the Merger disrupts our current plans and operations or diverts management’s attention from its ongoing business; the effects of the Merger on our business, operating results, and ability to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom we do business; the risk that our stock price may decline significantly if the Merger is not consummated; the nature, cost and outcome of any legal proceedings related to the Merger; the financial and business impacts of COVID-19 on our operations and the operations of our customers, suppliers, governmental and private payers and others in the healthcare industry and beyond; labor shortages and increased turnover in our employee base; contractual, inflationary and other general cost increases, including with regard to costs of labor, raw materials and freight; federal laws governing the health care industry; governmental policies affecting O&P operations, including with respect to reimbursement; failure to successfully implement a new enterprise resource planning system or other disruptions to information technology systems; the inability to successfully execute our acquisition strategy, including integration of recently acquired O&P clinics into our existing business; changes in the demand for our O&P products and services, including additional competition in the O&P services market; disruptions to our supply chain; our ability to enter into and derive benefits from managed-care contracts; our ability to successfully attract and retain qualified O&P clinicians; and other risks and uncertainties generally affecting the health care industry. For additional information and risk factors that could affect the Company, see its Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the three months ended June 30, 2022, each as filed with the SEC. The information contained in this report is made only as of the date hereof, even if subsequently made available by the Company on its website or otherwise.

Additional Information and Where to Find It

This communication relates to the Merger of Hanger and Merger Sub, a subsidiary of Parent, pursuant to the terms of the Merger Agreement. Parent and Merger Sub are indirect subsidiaries of funds managed and advised by Patient Square Capital. On August 26, 2022, Hanger filed with the SEC and commenced mailing to stockholders the Proxy Statement and a proxy card with respect to a special meeting of stockholders to be held on September 30, 2022 to approve the Merger. Stockholders of Hanger are urged to read the Proxy Statement and other relevant materials because they will contain important information about Hanger, Parent, Merger Sub and the Merger. Stockholders may obtain a free copy of these materials and other documents filed by Hanger with the SEC at the SEC’s website at www.sec.gov, at Hanger’s website at corporate.hanger.com or by sending a written request to our Corporate Secretary at our principal executive offices at 10910 Domain Drive, Suite 300, Austin, Texas 78758.

Participants in the Solicitation

Hanger, its directors and certain of its executive officers and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the Merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Hanger’s stockholders in connection with the Merger and any direct or indirect interests they have in the Merger are set forth in the Proxy Statement. Information relating to the foregoing can also be found in Hanger’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 28, 2022 and Hanger’s definitive proxy statement for its 2022 Annual Meeting of Stockholders filed with the SEC on April 7, 2022. To the extent that holdings of Hanger’s securities have changed since the amounts set forth in the Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 20, 2022